The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Correcting the function of mutated hemoglobin with gene therapy for SCD
Akshat Jain, MD, MPH, FRCP, Loma Linda University, San Bernadino, CA, shares insights into the recently FDA-approved gene therapies for the treatment of sickle cell disease (SCD). Utilizing CRIPSR/Cas9 technology or lentiviral-based vectors, these therapies edit the genome to correct dysfunctional hemoglobin, preventing the sickling of red blood cells. This mitigates anemia and reduces pain ratings reported by patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
